Fig 2: PCC0208017 inhibited the activity of MARK3 and MARK4 and decreased the phosphorylation of Tau. (A) The effects of PCC0208017 on the kinase activity of MARK1, MARK2, MARK3 and MARK4 were detected by commercial kit, and the IC50 was calculated. (B) The effect of PCC0208017 on the kinase activity of a panel of 18 oncogenic kinases (100 nmol/L). (C) The effects of PCC0208017 on the phosphorylation of Tau after 24 h treatment were detected by Western blot assay in GL261 and U251 cells. (D) The effects of PCC0208017 on the phosphorylation of Tau after different time treatment were detected by western blot assay in GL261. (E) The effects of PCC0208017 on the expression of MARK1, MARK2, MARK3 and MARK4 after 24 h treatment were detected by Western blot assay in GL261. Data represent mean ± SD of three different experiments. ∗P < 0.05 compared with control group.